loxapine has been researched along with Affective Psychosis, Bipolar in 32 studies
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder." | 9.27 | PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Bukhanovskaya, O; Dobrovolskaya, N; Estrada, G; Montañés, F; Oudovenko, N; Popov, M; San, L; Vieta, E, 2018) |
| "The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder." | 9.24 | Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Estrada, G; Oudovenko, N; San, L; Vieta, E, 2017) |
| "Inhaled loxapine rapidly reduces acute agitation in patients with schizophrenia or bipolar disorder and is generally well tolerated." | 8.93 | Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ( Pollack, CV, 2016) |
| "To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES)." | 8.88 | Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. ( Citrome, L, 2012) |
| "To describe the efficacy and safety of inhaled loxapine, a new formulation of an older antipsychotic being developed for the treatment of agitation associated with schizophrenia or bipolar disorder." | 8.87 | Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. ( Citrome, L, 2011) |
| " Using this delivery method, loxapine was assessed for its antiagitation effects in schizophrenia and bipolar I disorder patients." | 7.79 | Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder. ( Owen, RT, 2013) |
| "A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate." | 7.73 | Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. ( Karama, S; Lal, S, 2006) |
| "Loxapine has been adopted in the management of a wide range of acute disturbances, such as agitation in psychosis." | 6.82 | Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. ( Baloche, E; Corruble, E; Llorca, PM; Nuss, P; P Garay, R, 2022) |
| "Loxapine is a well-established, first-generation antipsychotic agent." | 6.49 | Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. ( Keating, GM, 2013) |
| "The aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (IM) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar I disorder." | 5.27 | PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Bukhanovskaya, O; Dobrovolskaya, N; Estrada, G; Montañés, F; Oudovenko, N; Popov, M; San, L; Vieta, E, 2018) |
| " The aim is to include approximately 500 patients with schizophrenia or bipolar disorder who previously received and responded well to inhaled loxapine in the hospital setting." | 5.27 | Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial. ( Baleeiro Teixeira, T; Boldeanu, A; Garcia-Alonso, F; Gil, E, 2018) |
| "The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder." | 5.24 | Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. ( Estrada, G; Oudovenko, N; San, L; Vieta, E, 2017) |
| " To date, the only formulation administered via a non-intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia is inhaled loxapine." | 4.93 | Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. ( Citrome, L; Zeller, SL, 2016) |
| "Inhaled loxapine rapidly reduces acute agitation in patients with schizophrenia or bipolar disorder and is generally well tolerated." | 4.93 | Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ( Pollack, CV, 2016) |
| "To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES)." | 4.88 | Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. ( Citrome, L, 2012) |
| "To describe the efficacy and safety of inhaled loxapine, a new formulation of an older antipsychotic being developed for the treatment of agitation associated with schizophrenia or bipolar disorder." | 4.87 | Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. ( Citrome, L, 2011) |
| "Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients." | 3.91 | Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. ( Cole, JB; Driver, BE; Klein, LR; Mullinax, SZ; Nordstrom, KD; Wilson, MP, 2019) |
| "1 mg of loxapine administered outside the hospital to treat psychomotor agitation related to schizophrenia, bipolar disorder, or schizoaffective disorder." | 3.85 | [New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases]. ( Borraz-Clares, D; Cester-Martínez, A; Cortés-Ramas, JA; Pellicer-Gayarre, M, 2017) |
| " Using this delivery method, loxapine was assessed for its antiagitation effects in schizophrenia and bipolar I disorder patients." | 3.79 | Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder. ( Owen, RT, 2013) |
| "Inhalative loxapine which will come onto the market shortly, is an important new alternative medication for the treatment of agitation, restlessness and tension in patients with schizophrenia and bipolar disorders." | 3.79 | [Inhalative loxapine: old tried and trusted medication with new indications]. ( Juckel, G, 2013) |
| "A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate." | 3.73 | Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. ( Karama, S; Lal, S, 2006) |
| "Loxapine has been adopted in the management of a wide range of acute disturbances, such as agitation in psychosis." | 2.82 | Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. ( Baloche, E; Corruble, E; Llorca, PM; Nuss, P; P Garay, R, 2022) |
| "The early and correct assessment of psychomotor agitation (PMA) is essential to ensure prompt intervention by healthcare professionals to improve the patient's condition, protect healthcare staff, and facilitate future management." | 2.72 | The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review. ( De Berardis, D; Ducci, G; Galluzzo, A; Palumbo, C; Pompili, M; Rosso, G, 2021) |
| "Loxapine is a first-generation antipsychotic medication available in the United States in oral form for more than three decades." | 2.49 | Safety and efficacy review of inhaled loxapine for treatment of agitation. ( Currier, G; Walsh, P, 2013) |
| "Loxapine is a well-established, first-generation antipsychotic agent." | 2.49 | Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. ( Keating, GM, 2013) |
| "Loxapine is an older first-generation antipsychotic drug that is approved for the treatment of schizophrenia." | 1.38 | Now take a deep breath: inhaled loxapine for the treatment of acute agitation. ( Howland, RH, 2012) |
| "A case of nonketotic hyperglycemic coma associated with the recent introduction of loxapine is presented." | 1.27 | Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. ( Lesar, T; Tollefson, G, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.50) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 21 (65.63) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Nuss, P | 1 |
| Corruble, E | 1 |
| Baloche, E | 1 |
| P Garay, R | 1 |
| Llorca, PM | 1 |
| Fernandez, A | 1 |
| Pendaries, G | 1 |
| Dor, E | 1 |
| Askenazy, F | 1 |
| Thümmler, S | 1 |
| Pompili, M | 1 |
| Ducci, G | 1 |
| Galluzzo, A | 1 |
| Rosso, G | 1 |
| Palumbo, C | 1 |
| De Berardis, D | 1 |
| Ruch, T | 1 |
| Nuss, S | 1 |
| Yeruva, RR | 1 |
| Gao, Y | 1 |
| Tegin, G | 1 |
| Terrell, C | 1 |
| El-Mallakh, RS | 1 |
| San, L | 2 |
| Estrada, G | 2 |
| Oudovenko, N | 2 |
| Vieta, E | 2 |
| Jørgensen, TR | 2 |
| Emborg, C | 2 |
| Dahlen, K | 2 |
| Bøgelund, M | 2 |
| Carlborg, A | 2 |
| Cester-Martínez, A | 1 |
| Cortés-Ramas, JA | 1 |
| Borraz-Clares, D | 1 |
| Pellicer-Gayarre, M | 1 |
| Amodeo, G | 1 |
| Fagiolini, A | 1 |
| Sachs, G | 1 |
| Erfurth, A | 1 |
| Montañés, F | 1 |
| Dobrovolskaya, N | 1 |
| Bukhanovskaya, O | 1 |
| Popov, M | 1 |
| Gil, E | 1 |
| Garcia-Alonso, F | 1 |
| Boldeanu, A | 1 |
| Baleeiro Teixeira, T | 1 |
| Cole, JB | 1 |
| Klein, LR | 1 |
| Mullinax, SZ | 1 |
| Nordstrom, KD | 1 |
| Driver, BE | 1 |
| Wilson, MP | 1 |
| Pacciardi, B | 1 |
| Calcedo, A | 1 |
| Messer, T | 1 |
| Owen, RT | 1 |
| Currier, G | 1 |
| Walsh, P | 1 |
| Keating, GM | 1 |
| Juckel, G | 1 |
| Morrow, T | 1 |
| Zeller, SL | 1 |
| Citrome, L | 3 |
| Pollack, CV | 1 |
| Howland, RH | 1 |
| Kwentus, J | 1 |
| Riesenberg, RA | 1 |
| Marandi, M | 1 |
| Manning, RA | 1 |
| Allen, MH | 1 |
| Fishman, RS | 1 |
| Spyker, DA | 1 |
| Kehne, JH | 1 |
| Cassella, JV | 1 |
| Raghunath, A | 1 |
| Karama, S | 1 |
| Lal, S | 1 |
| Tollefson, G | 1 |
| Lesar, T | 1 |
| Ewert, AL | 1 |
| Kloek, J | 1 |
| Wells, B | 1 |
| Phelps, S | 1 |
| Steele, TE | 1 |
| Gojer, JA | 1 |
| Jeffries, J | 1 |
| Bezchlibnyk-Butler, K | 1 |
| Remington, G | 1 |
| Dubin, WR | 1 |
| Weiss, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting[NCT02525991] | Phase 4 | 323 participants (Actual) | Interventional | 2016-09-08 | Completed | ||
| An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department[NCT02877108] | 100 participants (Anticipated) | Observational | 2016-04-30 | Recruiting | |||
| An Open-Label, Randomized, Active Controlled Inpatient Trial Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder[NCT06093451] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation[NCT00721955] | Phase 3 | 314 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Placebo | 29 |
| Inhaled Loxapine 5 mg | 69 |
| Inhaled Loxapine 10 mg | 78 |
The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items. (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | -4.9 |
| Inhaled Loxapine 5 mg | -8.1 |
| Inhaled Loxapine 10 mg | -9.0 |
Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00721955)
Timeframe: Baseline and 2 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled Placebo | 3.0 |
| Inhaled Loxapine 5 mg | 2.1 |
| Inhaled Loxapine 10 mg | 1.9 |
10 reviews available for loxapine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2022 |
The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Agitation; Schizophrenia | 2021 |
Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Loxapine; Psychomotor Agitation; Sc | 2017 |
Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2019 |
Safety and efficacy review of inhaled loxapine for treatment of agitation.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2013 |
Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Drug Delivery Systems; Dry Powde | 2013 |
Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Disease Management; Emergency Se | 2016 |
Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2016 |
Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Aerosols; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Nebu | 2011 |
Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Ph | 2012 |
5 trials available for loxapine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Aripiprazole; | 2017 |
PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Dis | 2018 |
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase IV as Top | 2018 |
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.
Topics: Administration, Inhalation; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Fema | 2012 |
Rapid tranquilization: a comparison of thiothixene with loxapine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bipolar Disorder; Dibenzoxazepines; Double-Blind Meth | 1986 |
17 other studies available for loxapine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
[Malignant neuroleptic syndrome: An atypical case in an adolescent affected by bipolar I disorder associated with catatonic syndrome].
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Catatonia; Electroencephalography; Humans; Hypno | 2020 |
Inhaled loxapine for acute agitation in a psychiatric emergency service.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Emergency Services, Psychiatric; | 2021 |
Patient preferences for medicine administration for acute agitation: results from an internet-based survey of patients diagnosed with bipolar disorder or schizophrenia in two Nordic countries.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Denmark; Drug Administration Routes; Female; Humans; | 2018 |
[New medical approach to out-of-hospital treatment of psychomotor agitation in psychiatric patients: a report of 14 cases].
Topics: Administration, Inhalation; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Drug Evaluation; Em | 2017 |
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Emergency Service, Hospital; Ethics, Research; Female | 2019 |
Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Drug Delivery Systems; Humans; L | 2013 |
[Inhalative loxapine: old tried and trusted medication with new indications].
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Evidence-Based Medicine; Humans; | 2013 |
Old drug in new package promises to calm the agitated.
Topics: Administration, Inhalation; Antipsychotic Agents; Bipolar Disorder; Humans; Loxapine; Psychomotor Ag | 2014 |
The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antipsychotic Agents; Bipolar Disorder; Fem | 2016 |
Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Antipsychotic Agents; Bipolar Disorder; Dose-Re | 2012 |
Repeated activation of mania by atypical antipsychotics in a patient.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combinatio | 2012 |
Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up.
Topics: Activity Cycles; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benztropine; Bipola | 2006 |
Nonketotic hyperglycemia associated with loxapine and amoxapine: case report.
Topics: Amoxapine; Bipolar Disorder; Diabetic Coma; Dibenzoxazepines; Female; Humans; Hyperglycemic Hyperosm | 1983 |
Neuroleptic malignant syndrome associated with loxapine.
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Dibenzoxazepines; Female; Fever; Humans; Loxapine | 1983 |
"Refractory" patients and loxapine: schizophrenia or mania?
Topics: Bipolar Disorder; Diagnosis, Differential; Dibenzoxazepines; Humans; Loxapine; Schizophrenia | 1982 |
Possible manic side-effects of loxapine.
Topics: Adult; Bipolar Disorder; Humans; Loxapine; Male; Schizophrenia | 1992 |
Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient.
Topics: Adult; Amenorrhea; Bipolar Disorder; Female; Fluvoxamine; Galactorrhea; Humans; Loxapine | 1992 |